Ortho SuperSite -- TORONTO — Investigators at the Cleveland Clinic quantified on- and off-label use of a recombinant human bone morphogenetic protein for spine fusion surgery in Medicare and non-Medicare patients, estimating the product’s sales at about three times greater in 2007 than in 2003.
